Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey
<i>Background/Objectives</i>: Metastatic testicular germ cell tumor (mGCT) is a highly curable disease with first-line cisplatin-based combination chemotherapy. This study aims to evaluate the clinicopathological characteristics and survival outcomes of patients with metastatic testicula...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/6/951 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849705981222584320 |
|---|---|
| author | Gul Sema Yildiran Keskin Ozge Yetginoglu Sertac Vurgun Evrican Zin Guzel Fariz Emrah Ozkan Mesut Yilmaz Cem Murat Soylemez Yesim Agyol Sinem Akbas Muhammed Fatih Sagiroglu Gizem Yildirim Huseyin Salih Semiz Ali Murat Tatli Ferhat Ekinci Ramazan Cosar Ramazan Acar Musa Baris Aykan Ismail Erturk Nuri Karadurmus |
| author_facet | Gul Sema Yildiran Keskin Ozge Yetginoglu Sertac Vurgun Evrican Zin Guzel Fariz Emrah Ozkan Mesut Yilmaz Cem Murat Soylemez Yesim Agyol Sinem Akbas Muhammed Fatih Sagiroglu Gizem Yildirim Huseyin Salih Semiz Ali Murat Tatli Ferhat Ekinci Ramazan Cosar Ramazan Acar Musa Baris Aykan Ismail Erturk Nuri Karadurmus |
| author_sort | Gul Sema Yildiran Keskin |
| collection | DOAJ |
| description | <i>Background/Objectives</i>: Metastatic testicular germ cell tumor (mGCT) is a highly curable disease with first-line cisplatin-based combination chemotherapy. This study aims to evaluate the clinicopathological characteristics and survival outcomes of patients with metastatic testicular cancer in a nationwide multicenter cohort. <i>Methods</i>: This multicenter retrospective cohort study included 316 male patients diagnosed with mGCT who were treated with first-line cisplatin-based chemotherapy across 10 institutions in Turkey between 2011 and 2024. Clinical and pathological data, including International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, treatment details, and survival outcomes, were analyzed. <i>Results</i>: The median age of the cohort was 28 years, and 76.3% of patients were diagnosed with non-seminoma. According to IGCCCG risk stratification, 53.2% had good-risk, 25.3% intermediate-risk, and 21.5% poor-risk disease. Median follow-up was 38.4 months. Among patients with seminoma, the 5-year overall survival (OS) rate was 100% in the good-risk group and 87.5% in the intermediate-risk group. In patients with non-seminoma, 5-year OS rates were 96.6%, 86.9%, and 65.1% in the good-, intermediate-, and poor-risk groups, respectively. Among 125 patients who received salvage treatment, high-dose chemotherapy (HDCT) significantly improved survival in the International Prognostic Factors Study Group (IPFSG) very high-risk group (3-year OS: 55.0% vs. 16.3% with conventional-dose chemotherapy (CDCT), <i>p</i> = 0.007). <i>Conclusions</i>: This study provides the first large-scale nationwide dataset on mGCT outcomes in Turkey, demonstrating overall survival rates comparable to international cohorts. The findings emphasize the importance of a multidisciplinary approach, adherence to treatment guidelines, and optimal surgical interventions in improving patient outcomes. |
| format | Article |
| id | doaj-art-73747feb145744bba71c2fe41b849f44 |
| institution | DOAJ |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-73747feb145744bba71c2fe41b849f442025-08-20T03:16:19ZengMDPI AGMedicina1010-660X1648-91442025-05-0161695110.3390/medicina61060951Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from TurkeyGul Sema Yildiran Keskin0Ozge Yetginoglu1Sertac Vurgun2Evrican Zin Guzel3Fariz Emrah Ozkan4Mesut Yilmaz5Cem Murat Soylemez6Yesim Agyol7Sinem Akbas8Muhammed Fatih Sagiroglu9Gizem Yildirim10Huseyin Salih Semiz11Ali Murat Tatli12Ferhat Ekinci13Ramazan Cosar14Ramazan Acar15Musa Baris Aykan16Ismail Erturk17Nuri Karadurmus18Department of Medical Oncology, Health Science University, Gulhane Research and Training Hospital, Ankara 06010, TurkeyDepartment of Medical Oncology, Dokuz Eylül University School of Medicine, Izmir 35210, TurkeyDepartment of Medical Oncology, Akdeniz University School of Medicine, Antalya 07058, TurkeyDepartment of Medical Oncology, Manisa Celal Bayar University School of Medicine, Manisa 45030, TurkeyDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03200, TurkeyDepartment of Medical Oncology, Sakarya Research and Training Hospital, Sakarya 54100, TurkeyDepartment of Medical Oncology, Izmir City Hospital, İzmir 35540, TurkeyDepartment of Medical Oncology, Marmara University School of Medicine, Istanbul 34854, TurkeyDepartment of Medical Oncology, Koc University Hospital, Istanbul 34010, TurkeyDepartment of Medical Oncology, Gaziantep City Hospital, Gaziantep 27470, TurkeyDepartment of Medical Oncology, Health Science University, Gulhane School of Medicine, Ankara 06010, TurkeyDepartment of Medical Oncology, Dokuz Eylül University School of Medicine, Izmir 35210, TurkeyDepartment of Medical Oncology, Akdeniz University School of Medicine, Antalya 07058, TurkeyDepartment of Medical Oncology, Manisa Celal Bayar University School of Medicine, Manisa 45030, TurkeyDepartment of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03200, TurkeyDepartment of Medical Oncology, Ufuk University School of Medicine, Ankara 06510, TurkeyDepartment of Medical Oncology, Health Science University, Gulhane School of Medicine, Ankara 06010, TurkeyDepartment of Medical Oncology, Health Science University, Gulhane School of Medicine, Ankara 06010, TurkeyDepartment of Medical Oncology, Health Science University, Gulhane School of Medicine, Ankara 06010, Turkey<i>Background/Objectives</i>: Metastatic testicular germ cell tumor (mGCT) is a highly curable disease with first-line cisplatin-based combination chemotherapy. This study aims to evaluate the clinicopathological characteristics and survival outcomes of patients with metastatic testicular cancer in a nationwide multicenter cohort. <i>Methods</i>: This multicenter retrospective cohort study included 316 male patients diagnosed with mGCT who were treated with first-line cisplatin-based chemotherapy across 10 institutions in Turkey between 2011 and 2024. Clinical and pathological data, including International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, treatment details, and survival outcomes, were analyzed. <i>Results</i>: The median age of the cohort was 28 years, and 76.3% of patients were diagnosed with non-seminoma. According to IGCCCG risk stratification, 53.2% had good-risk, 25.3% intermediate-risk, and 21.5% poor-risk disease. Median follow-up was 38.4 months. Among patients with seminoma, the 5-year overall survival (OS) rate was 100% in the good-risk group and 87.5% in the intermediate-risk group. In patients with non-seminoma, 5-year OS rates were 96.6%, 86.9%, and 65.1% in the good-, intermediate-, and poor-risk groups, respectively. Among 125 patients who received salvage treatment, high-dose chemotherapy (HDCT) significantly improved survival in the International Prognostic Factors Study Group (IPFSG) very high-risk group (3-year OS: 55.0% vs. 16.3% with conventional-dose chemotherapy (CDCT), <i>p</i> = 0.007). <i>Conclusions</i>: This study provides the first large-scale nationwide dataset on mGCT outcomes in Turkey, demonstrating overall survival rates comparable to international cohorts. The findings emphasize the importance of a multidisciplinary approach, adherence to treatment guidelines, and optimal surgical interventions in improving patient outcomes.https://www.mdpi.com/1648-9144/61/6/951testicular cancermetastatic germ cell tumorchemotherapyIGCCCGseminomanon-seminoma |
| spellingShingle | Gul Sema Yildiran Keskin Ozge Yetginoglu Sertac Vurgun Evrican Zin Guzel Fariz Emrah Ozkan Mesut Yilmaz Cem Murat Soylemez Yesim Agyol Sinem Akbas Muhammed Fatih Sagiroglu Gizem Yildirim Huseyin Salih Semiz Ali Murat Tatli Ferhat Ekinci Ramazan Cosar Ramazan Acar Musa Baris Aykan Ismail Erturk Nuri Karadurmus Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey Medicina testicular cancer metastatic germ cell tumor chemotherapy IGCCCG seminoma non-seminoma |
| title | Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey |
| title_full | Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey |
| title_fullStr | Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey |
| title_full_unstemmed | Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey |
| title_short | Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey |
| title_sort | survival outcomes in metastatic germ cell tumors a multicenter study from turkey |
| topic | testicular cancer metastatic germ cell tumor chemotherapy IGCCCG seminoma non-seminoma |
| url | https://www.mdpi.com/1648-9144/61/6/951 |
| work_keys_str_mv | AT gulsemayildirankeskin survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT ozgeyetginoglu survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT sertacvurgun survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT evricanzinguzel survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT farizemrahozkan survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT mesutyilmaz survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT cemmuratsoylemez survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT yesimagyol survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT sinemakbas survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT muhammedfatihsagiroglu survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT gizemyildirim survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT huseyinsalihsemiz survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT alimurattatli survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT ferhatekinci survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT ramazancosar survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT ramazanacar survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT musabarisaykan survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT ismailerturk survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey AT nurikaradurmus survivaloutcomesinmetastaticgermcelltumorsamulticenterstudyfromturkey |